reSET and reSET-O
Pear Therapeutics’s reSET is a 90-day prescription digital therapeutic for substance use disorder.
San Francisco–based Pear Therapeutics designed the device to provide cognitive behavioral therapy as an addition to contingency management for people who are 18 years or older and enrolled in outpatient treatment.
Pear Therapeutics describes the reSET-O as an 84-day prescription digital therapeutic for opioid use disorder. It increases retention of patients in outpatient treatment by providing cognitive behavioral therapy as an addition to outpatient treatment that includes transmucosal buprenorphine and contingency management.
Both of Pear Therapeutics’s platforms have a dashboard for clinicians and other healthcare providers to view information about a patient’s use of the systems, including lessons completed, patient-reported substance use, patient-reported cravings and triggers, patient-reported medication use, compliance rewards and in-clinic data inputs.
Pear Therapeutics announced in June this year that it would go public through a SPAC merger with Thimble Point Acquisition Corp.
The company won FDA clearance for the digital opioid addiction treatment app in December 2018 and was named a nominee in Prix Galien’s best medical technology awards in 2020.